ArticleJournal of physiology and biochemistry2026
Dieckol suppresses lipid accumulation and promotes thermogenic markers in 3T3-L1 adipocytes via ERK/p38 MAPK signaling.
Article in Journal of physiology and biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Thermogenic programming of adipocytes represents a promising strategy to enhance energy expenditure; however, most pharmacological browning agents activate PPARγ, which simultaneously promotes lipid accumulation and adipocyte hypertrophy. This study aimed to investigate whether dieckol induces thermogenic markers during adipocyte differentiation under conditions of restrained adipogenic commitment and to elucidate the involvement of MAPK and Nrf2 signaling pathways. 3T3-L1 preadipocytes were differentiated in the presence of dieckol (5-25 µM). Lipid accumulation, lipolytic activity, and intracellular reactive oxygen species were assessed using Oil Red O staining, enzymatic assays, and fluorescence analysis. Protein expression and signaling pathway activation were evaluated by Western blotting using pharmacological inhibitors of ERK1/2 (PD98059) and p38 MAPK (SB203580). Dieckol increased the expression of PRDM16, PGC-1α, and UCP1 while concurrently suppressing PPARγ, C/EBPα, and lipogenic marker expression, resulting in reduced intracellular triglyceride and cholesterol accumulation. Dieckol also enhanced lipolytic signaling and glycerol release, activated ERK1/2- and p38-dependent MAPK signaling, and promoted nuclear translocation of Nrf2 with increased activities of SOD, GPx, and CAT. Inhibition of MAPK signaling, particularly ERK1/2, attenuated dieckol-induced thermogenesis-associated modulation and lipid metabolic regulation. In conclusion, dieckol promotes thermogenic markers in differentiating 3T3-L1 adipocytes through coordinated ERK/p38 MAPK and Nrf2 signaling, enhancing UCP1 expression and lipolysis while suppressing lipid accumulation and adipogenic markers.
Indexed as
Identifiers
42530711What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.